Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Has Average Target Price of $16.20 According to Analysts

Key Points

• Analyst sentiment is moderately bullish: Six analysts give Xeris Biopharma a consensus “Moderate Buy” rating and an average 12-month price target of $16.20; several firms recently raised their targets.
• Quarterly results beat expectations: Xeris reported earnings of $0.06 per share versus $0.03 expected and revenue of $107.23 million versus a $101.68 million consensus.
• Shares opened at $15.86, near the reported 52-week high of $15.94. Company insiders sold a combined 173,332 shares over the past three months, with the transactions made under pre-arranged trading plans.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) has earned an average rating of "Moderate Buy" from the six brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $16.20.

Several equities research analysts have issued reports on the stock. Barclays boosted their price objective on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 6th. Wall Street Zen raised shares of Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Oppenheimer restated an "outperform" rating and set a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a report on Friday. Leerink Partners upped their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an "outperform" rating in a research report on Thursday, September 10th. Finally, HC Wainwright upped their price target on shares of Xeris Biopharma from $10.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday.

Xeris Biopharma Trading Up 4.3%

Shares of XERS opened at $15.86 on Tuesday. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The firm has a market capitalization of $2.89 billion, a P/E ratio of -317.14 and a beta of 0.61. The stock's fifty day simple moving average is $9.77 and its 200 day simple moving average is $7.66. Xeris Biopharma has a twelve month low of $5.25 and a twelve month high of $15.94.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The firm had revenue of $107.23 million for the quarter, compared to analysts' expectations of $101.68 million. On average, equities research analysts forecast that Xeris Biopharma will post 0.07 earnings per share for the current year.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, insider Steven Pieper sold 5,000 shares of the business's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $51,150.00. Following the transaction, the insider owned 1,346,053 shares in the company, valued at $13,770,122.19. The trade was a 0.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of the company's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $255,750.00. Following the completion of the sale, the insider directly owned 1,086,130 shares of the company's stock, valued at $11,111,109.90. The trade was a 2.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 173,332 shares of company stock valued at $1,721,471 over the last three months. 4.35% of the stock is owned by company insiders.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Xeris Biopharma in the 2nd quarter valued at about $115,042,000. Wellington Management Group LLP boosted its holdings in shares of Xeris Biopharma by 8.9% during the second quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company's stock valued at $18,732,000 after acquiring an additional 193,749 shares during the period. Legal & General Group Plc bought a new stake in Xeris Biopharma in the 2nd quarter valued at about $15,941,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Xeris Biopharma in the second quarter valued at approximately $14,316,000. Finally, Algert Global LLC increased its stake in shares of Xeris Biopharma by 50.6% in the second quarter. Algert Global LLC now owns 1,742,942 shares of the company's stock valued at $13,804,000 after purchasing an additional 585,984 shares during the period. Hedge funds and other institutional investors own 42.75% of the company's stock.

About Xeris Biopharma

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative.

The company also develops drug-delivery technologies intended to make medicines easier to store and administer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.